Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kyntra Bio Inc (KYNB)

Kyntra Bio Inc (KYNB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 28,854
  • Shares Outstanding, K 4,047
  • Annual Sales, $ 29,620 K
  • Annual Income, $ -47,580 K
  • EBIT $ -124 M
  • EBITDA $ -123 M
  • 60-Month Beta 0.84
  • Price/Sales 4.59
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 56.42%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Expected Move (DTE 0) N/A (0.00%)
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A
  • Expected Range N/A to N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -3.36
  • Number of Estimates 2
  • High Estimate -2.86
  • Low Estimate -3.85
  • Prior Year -4.00
  • Growth Rate Est. (year over year) +16.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.67 +5.85%
on 03/06/26
8.11 -12.95%
on 02/24/26
-0.99 (-12.30%)
since 02/23/26
3-Month
6.67 +5.85%
on 03/06/26
9.75 -27.59%
on 01/07/26
-1.37 (-16.25%)
since 12/23/25
52-Week
4.85 +45.57%
on 06/30/25
12.60 -43.97%
on 09/03/25
-0.82 (-10.35%)
since 03/21/25

Most Recent Stories

More News
Kyntra Bio: Q4 Earnings Snapshot

Kyntra Bio: Q4 Earnings Snapshot

KYNB : 7.06 (-0.98%)
Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and remains...

KYNB : 7.06 (-0.98%)
Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results

SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 after...

KYNB : 7.06 (-0.98%)
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026

FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC),...

KYNB : 7.06 (-0.98%)
FGEN : 9.71 (+7.65%)
Kyntra Bio to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), today announced that the company’s management will participate in the following investor...

KYNB : 7.06 (-0.98%)

Business Summary

Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Kyntra Bio, formerly known as FibroGen Inc., is based in SAN FRANCISCO.

See More

Key Turning Points

3rd Resistance Point 7.51
2nd Resistance Point 7.39
1st Resistance Point 7.23
Last Price 7.06
1st Support Level 6.95
2nd Support Level 6.83
3rd Support Level 6.67

See More

52-Week High 12.60
Fibonacci 61.8% 9.64
Fibonacci 50% 8.73
Fibonacci 38.2% 7.81
Last Price 7.06
52-Week Low 4.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.